Aims and objectives
Breast cancer is the most common primary tumour in women.
Its incidence increases with age,
with almost one half appearing in women older than 65 years old.
It is the most important risk factor for most women.
As the age increases,
so do their comorbidities and surgical risk,
as well as their physiological reserves diminishes.This is the reason why sometimes it is not possible to follow the optimal treatment option.
However,
there is a higher rate of low-risk tumours in older women compared with younger...
Methods and materials
We conducted a retrospective study in our institution from the year 2010 onwards,
in which we included 67 women,
with diagnosis of hormone-receptor positive breast cancer and important comorbidities that prevented the use of surgery as treatment so hormone therapy was used as primary treatment.
It has been carried out a radiological follow-up to evaluate the tumour evolution and treatment efficacy.
Clinical and radiological follow-up was personalized considering the necessities of each patient.
They were being controlled at least every 6 months,
with mammography and...
Results
The study included 67 women between the ages of 55 and 94 years old (mean: 83,8 years; median: 85 years) who were diagnosed with hormone-receptor positive breast cancer (53,1 % Luminal A and 46,9% Luminal B).
The diagnosis was made with core needle biopsy guided with sonography in the vast majority of cases.
Ductal carcinoma was the most frequent histologic type,
as it is in younger women,
but it has been seen some characteristics more related to breast cancer in old patients,
higher rates of...
Conclusion
This study has shown that hormone therapy is a good alternative to take into account when undergoing surgical treatment is not possible.
Endocrine therapy is recommended for most women with hormone receptor-positive breast cancer [10],
and can play a key role in patients who cannot be subject to surgery alternative,
as was the case in our study.
With the use of hormone therapy and a tight radiological follow-up,
the possibilities of hormone therapy can be maximized with the utmost benefit.
Personal information
Presenter: Diego Dominguez Conde
University Hospital of A Coruña - Department of Radiology
As Xubias
CP 15006
A Coruña,
Spain
e-mail:
[email protected]
References
[1] Keeson EM,
Allardice GM,
George WD,
Burns HJ,
Morrison DS.
Effects of multidisciplinary team working on breast cancer survival: retrospective,
comparative,
interventional cohort study of 13722 patients.
BMJ; 2012;344:e2718
[2] Macaskill EJ,
Renshaw L,
Dixon JM: Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer.
Oncologist 2006;11:1081–1088
.
[3]Diab SG,
Elledge RM,
Clark GM.
Tumor characteristics and clinical outcome of elderly women with breast cancer.
J Natl Cancer Inst 2000; 92:550.
[4] Quiroga-Garcia V,
Cirauqui-Cirauqui B,...